Cypress finally succumbs to Ramius
This article was originally published in Scrip
Ending the second long-running acquisition saga of the week, Cypress Bioscience has agreed to be bought by Ramius, who pulled in Royalty Pharma to help increase its offer from the original $4.00 per share to $6.50 per share in cash, raising the value of the deal to $255 million.
You may also be interested in...
Cerulean and privately-held Daré entered into a stock purchase agreement that will give the latter company's shareholders a majority stake in the combined company, which will focus on women's health – particularly contraceptives – instead of the former firm's nanoparticle-drug conjugates for cancer.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.